COMP <GO>
SMMT vs BMRN // FORWARD P/E MULTIPLE
Summit Therapeutics Inc. (NASDAQ) VS. BioMarin Pharmaceutical Inc. (NASDAQ) • 15-METRIC TALLY: SMMT 3
— BMRN 8
▲ FORWARD P/E MULTIPLE LEADER: BMRN
LAST: $14.80 (-7.67%) • MKT CAP: $12.82B
forward-pe
34.0x
LAST: $57.44 (-1.83%) • MKT CAP: $11.33B
forward-pe
26.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SMMT VS. BMRN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SMMT | BMRN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 77.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 6.00% | -41.00 | BMRN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 21.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.50% | 6.51% | -9.01 | BMRN | /fcf-yield <GO> |
| Operating Margin | -36.30% | 12.70% | -49.00 | BMRN | /operating-margins <GO> |
| Net Profit Margin | -29.80% | 10.80% | -40.60 | BMRN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.00% | 12.90% | -1.90 | BMRN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.57 | +20.43 | SMMT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | BMRN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.5 | 54.4 | -3.90 | BMRN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 0.95 | +0.02 | SMMT | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 34.0x | 26.8x | +7.20 | BMRN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.82B | $11.33B | $1.49B | SMMT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SMMT REV | BMRN REV | SMMT GROSS % | BMRN GROSS % | SMMT FCF | BMRN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.57B | $3.22B | — | 77.7% | -$323.6M | $725.0M |
| FY 2024 | $632.8M | $2.85B | — | 79.7% | -$142.2M | $487.4M |
| FY 2023 | $1.71B | $2.42B | — | — | -$76.8M | $50.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SMMT // BETA 0.97
BMRN // BETA 0.95